On the morning of February 12th Beijing time, according to Bloomberg, Google Ventures (GV), a subsidiary of Google's parent company Alphabet, recently recruited renowned executive David Schenkein from the biotechnology industry, who will be responsible for GV's investment in the life sciences field. This reflects Google's continuous development ambition in the healthcare field.Scone Kane was a hematologist and oncologist before, and also the CEO of Agios, a biotechnology company. Under his leadership, Agios developed two cancer drugs approved by the United States within 10 years, turning from a small start-up company to a large biotechnology company with a market value of 3.1 billion dollars, which is rare in the industry. Currently, Skeenkane is still the chairman of Agios.Last year, Skeenkane stepped down from the CEO position but still held the position of Chairman. At that time, people in the biotechnology industry were very concerned about his future direction. Skeenkane, who is 61 years old, once stated that retirement is impossible: "I can't even make it through a weekend, let alone retire. I know I want to continue my career, expand my influence in healthcare, and bring greater help to patients, but the methods may be differentApple, Amazon, and Microsoft are increasingly valuing the healthcare industry. However, pharmaceutical startups have high risks and a high degree of specialization, so traditional technology investors and enterprises are very cautious when investing.But GV is an exception as it has invested in some consumer oriented healthcare companies, such as Classpass and 23andMe, as well as in some pharmaceutical companies.I can't think of a company that has such a wide range of business in the healthcare industry. It provides healthcare services, is involved in healthcare insurance, and has a wide penetration into the entire healthcare industryIn 2000, Agios was still a private company when it was preparing to raise funds, and at that time, Skeenkane had connections with GV. At that time, a friend suggested that Skeenkane send an email to GV partner Krishna Yeshwant to seek financing.At first, Skeenkane thought he had found the wrong person, He said, "I received a reply saying that he wanted to see me. That night, we called. The next morning, we met at Brigham and Women's Hospital, and went to the cafeteria to have a cup of coffee." Scrinkaine told his friends, "Did you give the wrong email address? The person who received the email is just the resident doctor of Brigham and Women's Hospital, and there is no point in contacting him."Yeshvante is a hospital resident and also responsible for GV investment affairs. The two became friends at first sight. When Skeenkane said he wanted to retire from Agios, the two had a conversation and it was there that he had the idea of working for GV.

The relationship between AI and doctors is not about who replaces who, but about mutual improvement and empowerment of healthcare. This is the attitude of Qiao Xin, CEO of Shenrui Medical, and the goal of Shenrui Medical's future development.For Shenrui, 2018 was an extraordinary year. Established only one year ago, Shenrui completed its third round of financing in that year, with a total financing amount of up to 300 million yuan, setting the fastest financing speed in the industry. With the joint assistance of technology and funding, Shenrui has successfully entered the forefront of artificial intelligence and become an indispensable force in the research and development of medical artificial intelligence.As one of the youngest medical AI companies, Shenrui has become the most energetic enterprise in imaging AI in a short period of time, with its research and development strength ranking among the top in the entire industry. Is it talent that endows Shen Rui with a soul? Or did data forge its power? The path that Shen Rui has taken is worth exploring.Practitioners in life sciences need to experienceMedical care is different from other industries, and its vast knowledge structure requires practitioners to accumulate long-term experience. Qiao Xin, CEO of Shenrui Medical, has more than 20 years of experience in Siemens Healthineers Imaging Business Unit, enabling him to have a deep understanding of the real needs of each stage of enterprise development.Qiao Xin said, "At this stage, the ability of artificial intelligence comes from people; it is through sketching, programming, and other methods that people gradually implant the wisdom in the human brain into software - its core is still human. Therefore, the most core advantage of Shenrui comes from talentSince its establishment, Shenrui has placed talent at its core. After a year of development, our research institute has reached 80 people, among which the leading figure, Professor Yu Yizhou, was recently elected as an outstanding scientist at the 2018 ACM and was selected for the 2019 IEEE Fellow. Under his leadership, Shenrui Research Institute has become increasingly powerful, continuously providing inexhaustible impetus for Shenrui's developmentThe remaining members of the research institute are also outstanding in the industry. Their intelligent professional model algorithm team is composed of doctoral and senior researchers from Peking University, Chinese Academy of Sciences, and Stanford University. 70% of the members have published articles at top conferences such as ICCV, AAAI, and CVPR. In addition, the team also has many imaging and management experts who have worked in medical multinational companies for many years.Establishing advantages through technologyIn the eyes of the outside world, Shen Rui seems to have not been exposed very frequently. He is more like a hermit who continuously cultivates internal skills in order to accumulate and accumulate wealth. Shenrui has put more effort into technology research and development, and the iterative updates of technology are often not easily detected by the outside world. It is precisely because of this development mode that Sunrui, which was founded only one year and six months ago, has launched seven AI related product lines, including tumor, stroke, breast, image cloud... Sunrui has introduced AI products into various diseases with the highest incidence of incidence rate in China.The frequent positive reviews from frontline doctors helped Shen Rui submit the perfect answer sheet for 2018. In the special issue of the 40th anniversary of China Daily's reform and opening up in December 2018, Sunrise Healthcare, Ali and Geely Auto Automobile, as representatives of private enterprises, demonstrated the courage of Chinese private enterprises to seize the opportunity from the trend of global intelligent transformation and compete fiercely with international competitors by virtue of independently developed technologies.But even Shenrui, which has 7 product lines, has only opened a small gap in artificial intelligence and medical treatment, expanding into only the tip of the iceberg. This means that there is a huge space waiting for Shenrui to explore, and the hidden market in the field of artificial intelligence means it is difficult for us to evaluate how much potential Shenrui has.Therefore, in the new year, Shenrui's core strength will balance the upgrading of existing products with the breakthrough of new diseases. Although the existing products have been widely recognized by experts, there is still great room for improvement in AI technology. Shenrui Medical has a core algorithm team that is second to none in the industry, which is the source of Shenrui's scientific research strength.Meanwhile, Shenrui always regards innovation as the core of its operations. Qiao Xin believes that innovation is an inexhaustible driving force for a company to survive for a long time, and it is the lifeline that determines the survival of the enterprise. Only by continuously launching products can we gain a first mover advantage in the market and break through the tight encirclement when AI technology matures in the future, occupying a strategic highland.Explore the UnknownTo this day, a new round of financing for Shenrui Medical is also being prepared. Qiao Xin said, "In future financing and development, we will not easily accept invitations from investors, but need to consider the strategic layout of investment institutions and understand what strategic value investors can bring to ShenruiAs of December, Shenrui has implemented its artificial intelligence products in nearly 300 hospitals. Shenrui's products are not only used in tertiary hospitals, but also in grassroots hospitals where Shenrui uses AI technology to benefit more people. At the same time, medical examination institutions are also an important direction for Shenrui's cooperation, and their cooperation has made significant progress in the near future.For the application scenario of physical examination, Qiao Xin believes that: Physical examination and diagnosis are two different scenarios: diagnosis focuses more on 'analysis', while physical examination only focuses on' detection '. However, this does not mean that physical examination reduces the algorithmic requirements of AI technology. In fact, the population for physical examination is large, and the requirements for physical examination vary for different diseases. To ensure the success rate of physical examination, we must do more research to ensure the effectiveness of its examination results, which actually increases our technical requirementsOf course, its core still lies in technological development. This is not a problem for Shenrui. Shenrui has a team that can overcome all difficulties and solve all technical problems, which is Shenrui's core competitivenessDifficult to measure valueThe valuation of medical AI companies has always been a challenge. In the absence of a clear commercialization path, many companies can only estimate the potential profit potential in the future based on the total market size and possible market share, and cannot even reach a consensus on future cash flow standards. Therefore, valuations brought about by different valuation methods often have significant differences. Even if the same data is submitted, the data itself lacks a standardized process. Therefore, it is difficult for the current valuation to reach an accurate value.A commonly used method is to determine whether the valuation of existing enterprises is reasonable by seeking the valuation of enterprises in the same field. Although there are still significant errors, there is also a certain reference value. Taking intelligent driving, which takes computer vision as its core technology, as an example, the industry's general valuation is above $1 billion, with most companies valuing between $1.1 billion and $2 billion.Artificial intelligence enterprises focused on the medical field generally have low valuations. As a landmark index of enterprise development, valuation represents the stage of enterprise development. As a reference indicator, many core values of enterprises, such as strong scientific research strength and huge development potential, cannot be reflected in valuation. However, Shenrui Medical has great potential and high room for improvement in this direction.In addition, the application of AI technology in the medical field is still in a rapid development stage, constantly expanding new territories. In the future, AI may be applied in pathology, surgery, and rehabilitation. The gradual realization of all future scenarios will bring more value to existing AI enterprises - they have won at the starting line.As the leader of AI+medical enterprises, Shenrui not only has talent advantages to support sustainable development, but also has the support of external resources such as policies and capital. These wealth will lead Shenrui to continue advancing in the future, Deeper and Wiser.

Coronary heart disease is a common cardiovascular disease, and its onset is often related to unhealthy lifestyles, including unhealthy diet (high fat, high cholesterol, high calories, etc.), smoking, excessive alcohol consumption, prolonged sitting, staying up late, lack of exercise, high stress, anxiety, depression, etc. Due to the existence of unhealthy lifestyle, coupled with the lack of physical activity and self-care awareness, the incidence rate and mortality of coronary heart disease are increasing year by year, and the incidence is getting younger and younger, which has become the "first killer" threatening human health.In recent years, percutaneous coronary intervention (PCI) has rapidly developed into a relatively mature minimally invasive technique and is also the main method of treating coronary heart disease.Coronary stents are commonly used medical devices in PCI, and implantation of stents can achieve the goal of supporting narrow blood vessels and improving blood flow supply. Up to now, it has gone through the stages of bare metal stents and metal drug stents, mainly made of stainless steel, cobalt chromium, or platinum chromium alloys. Currently, it has ushered in the era of bioabsorbable stents.The matrix material of NeoVas bioabsorbable stent is the internationally used medical grade absorbable material L-polylactic acid (PLLA), and the drug is the classic restenosis inhibitor Sirolimus. After being implanted into the human body, it undergoes three stages: blood vessel reconstruction, stent degradation and absorption, and vascular repair. After achieving the same function as metal stents to support narrow blood vessels, it can be completely absorbed by the human body within about 3 years, allowing patients to bid farewell to the "metal heart" and have no foreign objects left in the body, avoiding the extremely late safety risks caused by permanent retention of metal stents in the body. The vascular structure and function are restored to a healthy state, To achieve the goal of "vascular reconstruction". At the same time, magnetic resonance imaging can be performed after the operation of bioabsorbable stents, avoiding the drawbacks of metal stents. This is another revolution in the field of cardiovascular treatment after the metal stent "vascular recanalization", and another milestone in PCI technology.NeoVas bioabsorbable stent is a globally recognized second-generation bioabsorbable stent with excellent safety, developed by Lepu Medical after nearly ten years of experience and utilizing the company's technology accumulation in the stent field for nearly twenty years. The three-year clinical follow-up data shows that the long-term safety is much better than that of similar international stents; Compared with metal drug stents, there is no statistically significant difference in blood vessel reconstruction and safety. However, after stent degradation, the patient's blood vessels basically return to the elasticity of the original blood vessels, demonstrating statistical superiority and significant therapeutic advantages. Patients will receive greater and more full life cycle benefits, and can provide more excellent and diverse products and solutions for patients and doctors